Long-term extension study of admilparant for pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This study continues treatment with admilparant, an investigational drug for pulmonary fibrosis, to evaluate its long-term safety and tolerability. Participants who have already completed a prior admilparant study, such as IM027068 or IM0271015, and are tolerating the treatment well may be eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier trials IM027068 or IM0271015 and not stopped the study drug permanently.
- You must not have any medical condition that your doctor thinks could make it unsafe for you to participate.
- You must not have had any side effects that led to permanent stop of the study drug in the earlier trials.
- You must not have symptoms of heart failure at rest.
- You must not have had lung reduction surgery or a lung transplant.
- If you have pulmonary arterial hypertension, you must not have needed to switch from one to multiple blood pressure medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how a new drug (HRS-9813) interacts with two existing lung fibrosis drugs (pirfenidone and nintedanib) in healthy adults. The results will help doctors understand how to combine these medicines safely.
This trial tests whether combining two medications—nerandomilast (a new anti-inflammatory drug) and mycophenolate (an immunosuppressant you may already be taking)—can safely slow lung scarring in people with pulmonary fibrosis other than IPF. The goal is to help doctors decide if this combination is right for you.
This study looks at how patients with pulmonary fibrosis (lung scarring) make decisions about stopping or continuing anti-fibrosis medications, especially if they have had side effects. It may help doctors and patients understand the best treatment choices.
This study continues treatment for people who already completed a previous study with an Avalyn inhaled antifibrotic drug. It aims to check the long-term safety of the medication for patients with certain types of lung scarring.
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
This trial tests a new medicine, BI 765423, to see if it can improve lung function in people with IPF, a lung scarring disease. You can join whether or not you are already taking standard treatments like nintedanib or pirfenidone.
Hear when a new Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.